Allogene Therapeutics (NASDAQ: ALLO) is a leading biotechnology company developing innovative allogeneic CAR T therapies. These "off-the-shelf" treatments utilize cells from healthy donors, a significant advancement compared to existing therapies that rely on a patient's own cells. This pioneering approach aims to make advanced cancer treatment more scalable and accessible for patients globally.
On April 14, 2026, Citigroup maintained its "Outperform" rating for Allogene Therapeutics when the stock was priced at $3.06. This positive outlook is strongly supported by recent data from the company's pivotal ALPHA3 trial. The trial is evaluating its lead candidate, cema-cel, for treating Large B-cell Lymphoma (LBCL).
As reported by GlobeNewswire, the trial data demonstrates strong effectiveness. Patients treated with cema-cel achieved a 58.3% Minimal Residual Disease (MRD) clearance rate, indicating no detectable cancer cells remained. This rate is significantly higher than the 16.7% observed in the control group that did not receive the treatment.
The treatment also demonstrates a strong safety profile. No serious side effects were reported, and patients were managed in an outpatient setting. This is a key advantage, as it makes the therapy more convenient and potentially less expensive than treatments requiring hospitalization.
Following the news, Allogene Therapeutics' stock price increased by 12.5% to $3.06, with trading volume exceeding 86.6 million shares. The company, with a market capitalization of approximately $746 million, expects to complete trial enrollment by the end of 2027, with key results anticipated in 2027 and 2028.
